Advertisement
Canada markets close in 5 hours 31 minutes
  • S&P/TSX

    21,729.54
    -144.18 (-0.66%)
     
  • S&P 500

    5,010.59
    -61.04 (-1.20%)
     
  • DOW

    37,807.48
    -653.44 (-1.70%)
     
  • CAD/USD

    0.7295
    -0.0003 (-0.03%)
     
  • CRUDE OIL

    82.27
    -0.54 (-0.65%)
     
  • Bitcoin CAD

    87,448.28
    -2,329.48 (-2.59%)
     
  • CMC Crypto 200

    1,379.18
    -3.40 (-0.25%)
     
  • GOLD FUTURES

    2,335.40
    -3.00 (-0.13%)
     
  • RUSSELL 2000

    1,965.84
    -29.58 (-1.48%)
     
  • 10-Yr Bond

    4.7160
    +0.0640 (+1.38%)
     
  • NASDAQ

    15,497.32
    -215.43 (-1.37%)
     
  • VOLATILITY

    17.12
    +1.15 (+7.21%)
     
  • FTSE

    8,056.69
    +16.31 (+0.20%)
     
  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     
  • CAD/EUR

    0.6804
    -0.0015 (-0.22%)
     

Analysts’ Recommendations for Incyte in January 2018

Analysts’ Recommendations for Incyte in January 2018

As we discussed earlier, Incyte (INCY) reported a 41.6% rise in its revenue to $381.5 million in 3Q17. Further, Wall Street analysts expect a 26.7% rise in Incyte’s revenue to $413.8 million in 4Q17 and a 35.9% rise in its revenue to $1.5 billion for the entirety of 2017. Incyte’s stock price has fallen nearly 4.3% over the last 12 months and nearly 3.9% year-to-date in 2018.